<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna’s stock has slowly drifted down since this past August for various reasons that include impending competition from Novavax, to worries over COVID-19 side effects, to disappointing Q4 guidance. The stock has a one year forward PS ratio of 5.45, which is a cheap price to pay considering the company’s long-term prospects.
...read full article on Seeking Alpha
